Table 1

HCT patient characteristics (N = 954)

LGI GVHD (n = 144)†Non-GVHD diarrhea (n = 42)Liver GVHD (n = 16)†Non-GVHD liver (n = 25)Skin GVHD (n = 337)No GVHD (n = 390)P
Age, y 
    Median (range) 52 (0-67) 46 (3-66) 44 (19-63) 35 (0-64) 48 (0-70) 46 (0-68) .001 
Disease 
    Malignant 94% (n = 135) 86% (n = 36) 100% (n = 16) 80% (n = 20) 94% (n = 317) 88% (n = 342) .005 
    Other 6% (n = 9) 14% (n = 6) 0% (n = 0) 20% (n = 5) 6% (n = 20) 12% (n = 48)  
Disease status at transplantation* 
    Low-/intermediate-risk 59% (n = 79) 67% (n = 24) 44% (n = 7) 75% (n = 15) 65% (n = 205) 66% (n = 226) .3 
    High-risk 41% (n = 56) 33% (n = 12) 56% (n = 9) 25% (n = 5) 35% (n = 112) 34% (n = 116)  
Donor type 
    Related donor 42% (n = 60) 52% (n = 22) 56% (n = 9) 68% (n = 17) 37% (n = 124) 58% (n = 228) < .001 
    Unrelated donor 58% (n = 84) 48% (n = 20) 44% (n = 7) 32% (n = 8) 63% (n = 213) 42% (n = 162)  
Donor match 
    Matched donor 71% (n = 102) 93% (n = 39) 81% (n = 13) 88% (n = 22) 73% (n = 245) 89% (n = 346) < .001 
    Mismatched donor 29% (n = 42) 7% (n = 3) 19% (n = 3) 12% (n = 3) 27% (n = 92) 11% (n = 44)  
Conditioning regimen intensity 
    High-intensity 53% (n = 77) 64% (n = 27) 69% (n = 11) 84% (n = 21) 54% (n = 181) 61% (n = 239) .02 
    Moderate-intensity 47% (n = 67) 36% (n =15) 31% (n = 5) 16% (n = 4) 46% (n = 156) 39% (n = 151)  
Grade of GVHD at onset 
    Grade 0 0% (n = 0) 100% (n = 42) 0% (n = 0) 100% (n = 25) 0% (n = 0) 100% (n = 390)  
    Grade I 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 69% (n = 231) 0% (n = 0)  
        Isolated skin stage 1 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 38% (n = 129) 0% (n = 0)  
        Isolated skin stage 2 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 30% (n = 102) 0% (n = 0)  
    Grade II 52% (n = 75) 0% (n = 0) 44% (n = 7) 0% (n = 0) 31% (n = 105) 0% (n = 0)  
        Isolated skin stage 3 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 31% (n = 105) 0% (n = 0)  
        GI or liver stage 1 52% (n = 75)† 0% (n = 0) 44% (n = 7) 0% (n = 0) 0% (n = 0) 0% (n = 0)  
    Grade III-IV 48% (n = 69) 0% (n = 0) 56% (n = 9) 0% (n = 0) < 1% (n = 1) 0% (n = 0)  
        Isolated skin stage 4 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) < 1% (n = 1) 0% (n = 0)  
        GI or liver stage 2 17% (n = 24)† 0% (n = 0) 38% (n = 6) 0% (n = 0) 0% (n = 0) 0% (n = 0)  
        GI or liver stage 3 18% (n = 26)† 0% (n = 0) 13% (n = 2) 0% (n = 0) 0% (n = 0) 0% (n = 0)  
        GI or liver stage 4 13% (n = 19)† 0% (n = 0) 6% (n = 1) 0% (n = 0) 0% (n = 0) 0% (n = 0)  
Days after HCT 
    Median (range) 30 (7-215) 21 (7-78) 33 (10-112) 21 (7-106) 28 (5-485) 30 (7-185) < .001 
LGI GVHD (n = 144)†Non-GVHD diarrhea (n = 42)Liver GVHD (n = 16)†Non-GVHD liver (n = 25)Skin GVHD (n = 337)No GVHD (n = 390)P
Age, y 
    Median (range) 52 (0-67) 46 (3-66) 44 (19-63) 35 (0-64) 48 (0-70) 46 (0-68) .001 
Disease 
    Malignant 94% (n = 135) 86% (n = 36) 100% (n = 16) 80% (n = 20) 94% (n = 317) 88% (n = 342) .005 
    Other 6% (n = 9) 14% (n = 6) 0% (n = 0) 20% (n = 5) 6% (n = 20) 12% (n = 48)  
Disease status at transplantation* 
    Low-/intermediate-risk 59% (n = 79) 67% (n = 24) 44% (n = 7) 75% (n = 15) 65% (n = 205) 66% (n = 226) .3 
    High-risk 41% (n = 56) 33% (n = 12) 56% (n = 9) 25% (n = 5) 35% (n = 112) 34% (n = 116)  
Donor type 
    Related donor 42% (n = 60) 52% (n = 22) 56% (n = 9) 68% (n = 17) 37% (n = 124) 58% (n = 228) < .001 
    Unrelated donor 58% (n = 84) 48% (n = 20) 44% (n = 7) 32% (n = 8) 63% (n = 213) 42% (n = 162)  
Donor match 
    Matched donor 71% (n = 102) 93% (n = 39) 81% (n = 13) 88% (n = 22) 73% (n = 245) 89% (n = 346) < .001 
    Mismatched donor 29% (n = 42) 7% (n = 3) 19% (n = 3) 12% (n = 3) 27% (n = 92) 11% (n = 44)  
Conditioning regimen intensity 
    High-intensity 53% (n = 77) 64% (n = 27) 69% (n = 11) 84% (n = 21) 54% (n = 181) 61% (n = 239) .02 
    Moderate-intensity 47% (n = 67) 36% (n =15) 31% (n = 5) 16% (n = 4) 46% (n = 156) 39% (n = 151)  
Grade of GVHD at onset 
    Grade 0 0% (n = 0) 100% (n = 42) 0% (n = 0) 100% (n = 25) 0% (n = 0) 100% (n = 390)  
    Grade I 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 69% (n = 231) 0% (n = 0)  
        Isolated skin stage 1 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 38% (n = 129) 0% (n = 0)  
        Isolated skin stage 2 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 30% (n = 102) 0% (n = 0)  
    Grade II 52% (n = 75) 0% (n = 0) 44% (n = 7) 0% (n = 0) 31% (n = 105) 0% (n = 0)  
        Isolated skin stage 3 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) 31% (n = 105) 0% (n = 0)  
        GI or liver stage 1 52% (n = 75)† 0% (n = 0) 44% (n = 7) 0% (n = 0) 0% (n = 0) 0% (n = 0)  
    Grade III-IV 48% (n = 69) 0% (n = 0) 56% (n = 9) 0% (n = 0) < 1% (n = 1) 0% (n = 0)  
        Isolated skin stage 4 0% (n = 0) 0% (n = 0) 0% (n = 0) 0% (n = 0) < 1% (n = 1) 0% (n = 0)  
        GI or liver stage 2 17% (n = 24)† 0% (n = 0) 38% (n = 6) 0% (n = 0) 0% (n = 0) 0% (n = 0)  
        GI or liver stage 3 18% (n = 26)† 0% (n = 0) 13% (n = 2) 0% (n = 0) 0% (n = 0) 0% (n = 0)  
        GI or liver stage 4 13% (n = 19)† 0% (n = 0) 6% (n = 1) 0% (n = 0) 0% (n = 0) 0% (n = 0)  
Days after HCT 
    Median (range) 30 (7-215) 21 (7-78) 33 (10-112) 21 (7-106) 28 (5-485) 30 (7-185) < .001 
*

High risk of disease status at HCT is according to Center for International Blood and Marrow Transplant Research guidelines.

†

With or without skin GVHD involvement.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal